Inspire Medical Systems (NYSE:INSP) Issues FY 2025 Earnings Guidance

Inspire Medical Systems (NYSE:INSP) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.400-0.500 for the period, compared to the consensus EPS estimate of 0.960. The company issued revenue guidance of $900.0 million-$910.0 million, compared to the consensus revenue estimate of $904.5 million.

Inspire Medical Systems Price Performance

Shares of NYSE:INSP opened at $78.96 on Tuesday. The business’s 50-day moving average is $98.63 and its 200-day moving average is $129.96. Inspire Medical Systems has a 1 year low of $73.92 and a 1 year high of $218.52. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of 45.64, a P/E/G ratio of 2.49 and a beta of 1.15.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.23. The firm had revenue of $217.09 million during the quarter, compared to analyst estimates of $214.50 million. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%.The company’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.32 EPS. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. Analysts anticipate that Inspire Medical Systems will post 2.16 EPS for the current year.

Inspire Medical Systems declared that its Board of Directors has authorized a stock repurchase plan on Monday, August 11th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to purchase up to 8.6% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

INSP has been the topic of several recent research reports. Truist Financial restated a “hold” rating and set a $125.00 target price (down previously from $190.00) on shares of Inspire Medical Systems in a research report on Tuesday, August 5th. Morgan Stanley dropped their price target on Inspire Medical Systems from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Tuesday, July 15th. UBS Group set a $89.00 price target on Inspire Medical Systems and gave the stock a “neutral” rating in a research note on Monday. KeyCorp downgraded shares of Inspire Medical Systems from an “overweight” rating to a “sector weight” rating in a research note on Tuesday, August 5th. Finally, Leerink Partners reduced their price target on Inspire Medical Systems from $116.00 to $97.00 and set a “market perform” rating on the stock in a report on Friday, August 15th. Seven analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Inspire Medical Systems presently has a consensus rating of “Moderate Buy” and a consensus price target of $154.43.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, CFO Richard Buchholz sold 11,000 shares of Inspire Medical Systems stock in a transaction on Friday, August 29th. The shares were sold at an average price of $93.39, for a total value of $1,027,290.00. Following the transaction, the chief financial officer directly owned 44,867 shares of the company’s stock, valued at approximately $4,190,129.13. The trade was a 19.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.30% of the company’s stock.

Institutional Investors Weigh In On Inspire Medical Systems

Several hedge funds have recently added to or reduced their stakes in the business. Daiwa Securities Group Inc. raised its position in shares of Inspire Medical Systems by 38.7% in the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock worth $60,000 after acquiring an additional 130 shares during the period. FORA Capital LLC purchased a new stake in shares of Inspire Medical Systems in the 2nd quarter valued at approximately $220,000. Quantinno Capital Management LP boosted its position in shares of Inspire Medical Systems by 113.9% during the 2nd quarter. Quantinno Capital Management LP now owns 3,207 shares of the company’s stock worth $416,000 after purchasing an additional 1,708 shares during the period. Tidal Investments LLC boosted its position in shares of Inspire Medical Systems by 171.9% during the 2nd quarter. Tidal Investments LLC now owns 3,630 shares of the company’s stock worth $471,000 after purchasing an additional 2,295 shares during the period. Finally, Engineers Gate Manager LP acquired a new stake in Inspire Medical Systems during the 2nd quarter worth approximately $473,000. 94.91% of the stock is owned by hedge funds and other institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.